Jaguar Animal Health

Jaguar Animal Health is a tradename of San Francisco, CA-based Jaguar Health, Inc., a commercial stage pharmaceuticals company that develops novel, plant-based, non-opioid, and sustainably derived prescription medicines for animals with chemotherapy-induced diarrhea (CID). On December 21, 2021, we received conditional approval to market Canalevia™-CA1 (crofelemer delayed-release tablets), our oral prescription drug for the treatment of CID in dogs. This is the first and only product indicated for the treatment of CID in dogs to receive any type of approval from FDA. See full Prescribing Information at Canalevia.com.

Important Safety Information About Canalevia-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia™-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.